Related Experiment Video
Updated: May 24, 2026
12:58
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Largazole: from discovery to broad-spectrum therapy.
1Department of Chemistry, Duke University, Durham, NC 27708, USA. jiyong.hong@duke.edu
Natural Product Reports
|February 16, 2012
Summary
Largazole, a marine natural product, potently inhibits histone deacetylases (HDACs) and selectively targets cancer cells. Its novel structure and anticancer potential are driving synthetic chemistry research and therapeutic investigations.
Area of Science:
- Marine natural products
- Medicinal chemistry
- Chemical biology
Background:
- Largazole is a cyclic depsipeptide from Symploca cyanobacteria with a unique structure.
- It exhibits potent inhibition of class I histone deacetylases (HDACs).
- Largazole shows selective growth-inhibitory activity against transformed cells.
Purpose of the Study:
- To survey recent advances in largazole research.
- To highlight synthetic chemistry efforts and biological investigations.
- To explore largazole's potential as a cancer therapeutic.
Main Methods:
- Discovery and structural elucidation of largazole.
- Development of synthetic routes to largazole.
- Target identification and structure-activity relationship (SAR) studies.
- X-ray crystallography of the HDAC8-largazole complex.
- In vivo studies of anticancer and osteogenic activities.
Main Results:
- Novel chemical scaffold of largazole identified.
- Potent inhibition of class I HDACs demonstrated.
- Differential activity favoring cancer cells observed.
- In vivo anticancer and osteogenic effects confirmed.
- HDAC8-largazole crystal structure elucidated.
Conclusions:
- Largazole is a promising marine natural product with significant anticancer potential.
- Ongoing synthetic and biological studies continue to uncover its therapeutic value.
- Its unique mechanism of action warrants further investigation for cancer therapy.
Related Concept Videos
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
01:30Development of Antibiotic Resistance
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...